| bibliographicCitation |
Diaz-Manera J, Kishnani PS, Kushlaf H, Ladha S, Mozaffar T, Straub V, Toscano A, van der Ploeg AT, Berger KI, Clemens PR, Chien Y, Day JW, Illarioshkin S, Roberts M, Attarian S, Borges JL, Bouhour F, Choi YC, Erdem-Ozdamar S, Goker-Alpan O, Kostera-Pruszczyk A, Haack KA, Hug C, Huynh-Ba O, Johnson J, Thibault N, Zhou T, Dimachkie MM, Schoser B, Behin A, Boentert M, Carvalho G, Chahin N, Charrow J, Deegan P, Durmus Tekce H, Duval F, Genge A, Gutmann L, Henderson RD, Hennermann JB, Hiwot T, Hughes D, Karaa A, Karam C, Kautzky-Willer A, Komaki H, Laforet P, Longo N, Malinova V, Maré R, Maxit C, Mengel E, Moggio MG, Molnár MJ, Mongini TE, Nadaj-Pakleza A, Nascimento Osorio A, Noury J, Oliveira ASB, Parman Y, Pena L, Remiche G, Sciacco M, Shieh PB, Smith C, Stulnig T, Taithe F, Tard C, Tarnopolsky M, Vorgerd M, Whitley C, Young P, Alonso-Pérez J, Altemus P, Aubé-Nathier A, Avelar JB, Bailey C, Bekircan-Kurt CE, Billy J, Boschi S, Brown KE, Carrera Garcia L, Chase L, Cirne H, Danjoux L, Davion J, DeArmey S, Fedotova E, Gandolfo E, Grosz Z, Guellec D, Guettsches A, Guglieri M, Hatcher E, Helms S, Hufgard-Leitner M, Klyushnikov SA, Langton J, Linková L, Mavroudakis N, Mazurová S, Mori M, Müller-Miny L, Musumeci O, Nance CS, Natera-de Benito D, Neel R, Niizawa GA, Noll L, Ortega E, Pasnoor M, Pautot V, Potulska-Chromik A, Pugliese A, Questienne C, Ramos Lopes M, Reyes-Leiva D, Riedl M, Rugiero MF, Salort-Campana E, Sgobbi Souza PV, Sole G, Solera L, Souto Lopes S, Specht S, Statland J, Swenson A, Tan CY, Tizon S, van der Beek NAME, van Kooten HA, Wencel M, Wenninger S, Zagnoli F. Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial. The Lancet Neurology. 2021 Dec;20(12):1012–26. doi: 10.1016/s1474-4422(21)00241-6. |